Amicus Therapeutics, Inc.
FOLD
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, aā¦ read more
Healthcare
Biotechnology
18 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$10.02
Price+1.57%
$0.15
1Y
Price
Market Cap
$3.092b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years+28.3%
EBITDA Margin+10.2%
Net Profit Margin+20.9%
Free Cash Flow MarginRevenue
$598.704m
+13.3%
1y CAGR+22.3%
3y CAGR+18.7%
5y CAGREarnings
-$14.061m
+74.9%
1y CAGR+58.0%
3y CAGR+44.9%
5y CAGREPS
-$0.04
+77.8%
1y CAGR+60.1%
3y CAGR+47.8%
5y CAGRBook Value
$230.424m
$868.811m
Assets$638.387m
Liabilities$442.821m
DebtDebt to Assets
51.0%
7.5x
Debt to EBITDAFree Cash Flow
$9.691m
+125.9%
1y CAGR+77.3%
3y CAGR+62.4%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company